IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, there are several case reports of chronic myelogenous leukemia patients developing PH after treatment with the tyrosine kinase inhibitor dasatinib [46]–[48] and, like IFNα, dasatinib has been shown to reverse experimental PH [49].